New imaging agent could improve detection of rare cancers
NCT ID NCT07621146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers and have their scans compared for accuracy and image quality.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-AmBF3TATE (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a more accessible or higher-quality imaging option for people with neuroendocrine tumors, potentially improving diagnosis and treatment planning.
What could go wrong
This is a small, early-phase study (51 participants) that only tests imaging accuracy, not treatment outcomes. The new tracer may not prove superior or may have unforeseen limitations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••